Geron’s RYTELO™ Receives Positive CHMP Opinion for Lower-Risk MDS
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on blood cancer treatments, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…